Atara Biotherapeutics(ATRA)
Search documents
Atara Biotherapeutics(ATRA) - 2021 Q1 - Earnings Call Transcript
2021-05-05 12:54
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q1 2021 Earnings Conference Call May 4, 2021 4:30 PM ET Company Participants Eric Hyllengren - Vice President of Investor Relations and Finance Pascal Touchon - President and Chief Executive Officer Jakob Dupont - Executive Vice President and Global Head of Research and Development Utpal Koppikar - Chief Financial Officer Joe Newell - Chief Operations Officer AJ Joshi - Chief Medical Officer Kristin Yarema - Chief Commercial Officer Conference Call Participants John ...
Atara Biotherapeutics(ATRA) - 2020 Q4 - Earnings Call Transcript
2021-03-02 03:51
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q4 2020 Earnings Conference Call March 1, 2020 4:30 PM ET Company Participants Eric Hyllengren - VP, IR & Finance Pascal Touchon - President and CEO Jakob Dupont - EVP and Global Head, Research & Development AJ Joshi - CMO Kristin Yarema - CCO Conference Call Participants John Newman - Canaccord Salim Syed - Mizuho Michael DiFiore - Evercore Anupam Rama - JPMorgan Ernie Rodriguez - Cowen and Co. Matt Phipps - William Blair Ken Chan - Jefferies Operator Good afternoo ...
Atara Biotherapeutics(ATRA) - 2020 Q3 - Earnings Call Transcript
2020-11-10 05:39
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q3 2020 Earnings Conference Call November 9, 2020 4:30 PM ET Company Participants Eric Hyllengren - Vice President of Investor Relations & Finance Pascal Touchon - President & Chief Executive Officer Jakob Dupont - Executive Vice President & Global Head of Research & Development Utpal Koppikar - Chief Financial Officer Joe Newell - Chief Operations Officer AJ Joshi - Chief Medical Officer Kristin Yarema - Chief Commercial Officer Conference Call Participants John Ne ...
Atara Biotherapeutics(ATRA) - 2020 Q3 - Quarterly Report
2020-11-09 21:11
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36548 ATARA BIOTHERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 46-0920988 (State or other jurisdicti ...